# Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

> **NCT00759200** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 525 (estimated)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** alb-interferon alfa 2b
- **DRUG:** alb-interferon alfa 2b
- **DRUG:** alb-interferon alfa 2b
- **DRUG:** alb-interferon alfa 2b
- **DRUG:** peg-interferon

## Key facts

- **NCT ID:** NCT00759200
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 525 (ESTIMATED)
- **Last updated:** 2016-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00759200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00759200, "Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00759200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*